Krka Logo

Krka

Develops and sells generic prescription, non-prescription, and animal health products globally.

KRKG | LJSE

Overview

Corporate Details

ISIN(s):
SI0031102120
LEI:
549300H9RLRTRTLRUZ73
Country:
Slovenia
Address:
Šmarješka cesta 006, 8501 Novo mesto
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Krka is a leading international generic pharmaceutical company focused on the development, production, marketing, and sale of human and animal health products. With over 70 years of experience, the company's core business is providing high-quality and innovative generic medicines. Its portfolio is composed of three main segments: prescription pharmaceuticals for treating common diseases, non-prescription products for minor illnesses and preventative care, and a range of animal health products. Krka's products are marketed globally, serving patients in more than 70 countries.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-01 08:30
Transaction in Own Shares
Terminski načrt programa odkupa lastnih delnic v prvem polletju 2026
English 110.6 KB
2025-12-01 08:30
Transaction in Own Shares
Terminski načrt programa odkupa lastnih delnic v prvem polletju 2026
Slovene 1.5 KB
2025-12-01 08:30
Transaction in Own Shares
Share buy-back programme schedule from January to June 2026
English 111.8 KB
2025-12-01 08:30
Transaction in Own Shares
Share buy-back programme schedule from January to June 2026
English 1.5 KB
2025-12-01 08:30
Transaction in Own Shares
Detailed report on acquisition of treasury shares
English 122.3 KB
2025-12-01 08:30
Transaction in Own Shares
Acquisition of treasury shares
English 2.3 KB
2025-12-01 08:30
Transaction in Own Shares
Podrobno poročilo o nakupih lastnih delnic
English 118.8 KB
2025-12-01 08:30
Transaction in Own Shares
Pridobivanje lastnih delnic
Slovene 2.1 KB
2025-12-01 08:30
Report Publication Announcement
Financial Calendar 2026
English 69.6 KB
2025-12-01 08:30
Report Publication Announcement
Financial calendar for 2026
English 1.0 KB
2025-12-01 08:30
Report Publication Announcement
Finančni koledar 2026
Slovene 104.0 KB
2025-12-01 08:30
Report Publication Announcement
Finančni koledar za leto 2026
Slovene 1.1 KB
2025-11-24 08:30
Transaction in Own Shares
Detailed report on acquisition of treasury shares
English 122.6 KB
2025-11-24 08:30
Transaction in Own Shares
Acquisition of treasury shares
English 2.2 KB
2025-11-24 08:30
Transaction in Own Shares
Podrobno poročilo o nakupih lastnih delnic
English 119.2 KB

Automate Your Workflow. Get a real-time feed of all Krka filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Krka

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Krka via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

L&C BIO Co., Ltd Logo
Develops tissue grafts, medical devices, and cosmetics for tissue regeneration medicine.
South Korea
290650
LEAP THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing targeted immuno-oncology antibody therapies for cancer.
United States of America
LPTX
Legend Biotech Corp Logo
Develops and commercializes CAR-T cell therapies for cancer, including CARVYKTI® for myeloma.
United States of America
LEGN
LENZ Therapeutics, Inc. Logo
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America
LENZ
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
Lidds AB Logo
Develops oncology drugs using a technology for local, controlled, and sustained drug release.
Sweden
LIDDS
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.